Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Protalix BioTherapeutics (PLX) over the last 16 years, with Q3 2025 value amounting to $124000.0.

  • Protalix BioTherapeutics' Change in Inventory rose 10352.27% to $124000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 19251.82%. This contributed to the annual value of $2.2 million for FY2024, which is 191.88% down from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' Change in Inventory is $124000.0, which was up 10352.27% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Change in Inventory ranged from a high of $4.0 million in Q4 2024 and a low of -$3.5 million during Q3 2024
  • Its 5-year average for Change in Inventory is $430157.9, with a median of $124000.0 in 2025.
  • Per our database at Business Quant, Protalix BioTherapeutics' Change in Inventory surged by 172010.05% in 2021 and then tumbled by 66781.61% in 2023.
  • Protalix BioTherapeutics' Change in Inventory (Quarter) stood at $3.2 million in 2021, then crashed by 30.46% to $2.2 million in 2022, then tumbled by 213.2% to -$2.5 million in 2023, then surged by 259.34% to $4.0 million in 2024, then plummeted by 96.93% to $124000.0 in 2025.
  • Its Change in Inventory stands at $124000.0 for Q3 2025, versus $1.6 million for Q2 2025 and -$1.7 million for Q1 2025.